Comparative Pharmacology
Head-to-head clinical analysis: CEFZIL versus CEPHAPIRIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFZIL versus CEPHAPIRIN SODIUM.
CEFZIL vs CEPHAPIRIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
500 mg to 1 g IM or IV every 6 hours.
None Documented
None Documented
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic